Furthermore, in combination with either fulvestrant or 4-hydroxytamoxifen, riluzole additively suppressed ER+ breast cancer cell growth in vitro, and significantly reduced proliferation in ex vivo primary breast tumor explant cultures. Here, ESR1 is linked to breast cancer.